Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0705-0001 · 1 trial · 2 indications
Measured in number of events.
Measured in number of events.
Measured in Hour x Micromole (hr×μM).
| Arm | Type | Description |
|---|---|---|
| Part A: NNC0705-0001 | EXPERIMENTAL | Participants will receive 6 different single ascending doses of NNC0705-0001 via oral administration. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive single ascending dose of placebo matching NNC0705-0001 via oral administration. |
| Part B: NNC0705-0001 | EXPERIMENTAL | Participants will receive 4 different multiple ascending doses of NNC0705-0001 via oral administration. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will receive multiple ascending doses of placebo matching NNC0705-0001 via oral administration. |
| Part C: NNC0705-0001 | EXPERIMENTAL | Participants will receive 2 separate single doses of NNC0705-0001 at a previously safety-cleared dose level in PART A, either in a fed or fasted state. |
| Name | Type | Description |
|---|---|---|
| NNC0705-0001 | DRUG | NNC0705-0001 will be administered orally. |
| Placebo | DRUG | Placebo matching NNC0705-0001 will be administered orally. |
Inclusion Criteria: * Men, or women of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. * Body weight: greater than or equal to ...
NNC0705-0001 is an investigational small molecule being developed by Novo Nordisk for use in healthy volunteers, with a study also including participants with chronic kidney disease. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC0705-0001 is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the NYSE under the ticker symbol NVO. The drug is an investigational small molecule in the nephrology therapeutic area.
NNC0705-0001 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory agency.
NNC0705-0001 has one completed Phase 1 trial, NCT07029568, titled "A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People." The trial enrolled 116 participants in the Netherlands, was randomized, double-blind, and placebo-controlled.
No alternative names for NNC0705-0001 have been disclosed. The drug is identified solely by its code name NNC0705-0001 in clinical trial registries and company communications.